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renal tissues from patients with anti-glomerular
basement membrane disease
Zhen Qu1, Zhao Cui1*, Gang Liu1 and Ming-hui Zhao1,2Abstract
Background: Renal injury of anti-glomerular basement membrane (GBM) disease is defined by the linear
deposition of IgG along GBM and rapidly progressive glomerulonephritis. To date, the distribution of anti-GBM IgG
subclasses on renal tissue is still unclear. In the current study, we investigated the deposition of the four IgG
subclasses using immunohistochemistry in the renal biopsy specimens from 46 patients with anti-GBM disease.
Results: All four IgG subclasses can be detected within the GBM. Anti-GBM IgG3 was detected in all patients
(100%), with 39 (84.8%) patients presenting with weak segmental staining and 7 (15.2%) patients with strong linear
deposition. Anti-GBM IgG2 was detected in 22 (47.8%) patients, with 20 (90.9%) patients having weak segmental
deposition and 2 (9.1%) patients presenting strong linear staining. Anti-GBM IgG1 and IgG4 were detected in 9
(19.6%) and 7 (15.2%) patients, respectively. IgG deposition along tubular basement membrane (TBM) was also
detected in 31 (67.4%) patients. Among them, the IgG subclass distribution was similar to that of the deposition
within the GBM: IgG1 6.5% (2/31), IgG2 45.2% (14/31), IgG3 100% (31/31) and IgG4 9.7% (3/31). We observed
increased inflammatory cell infiltration into the interstitium in patients with increased anti-TBM IgG3 deposits
(P=0.031).
Conclusions: Anti-GBM IgG3 predominantly deposits along GBM and TBM on renal biopsy specimens from patients
with anti-GBM disease, which may be involved in the development of renal injury of the disease.Background
Anti-glomerular basement membrane (GBM) disease, also
known as Goodpasture’s disease, is an organ specific auto-
immune disorder characterized by rapidly progressive
glomerulonephritis, pulmonary hemorrhage and presenta-
tion of anti-GBM autoantibodies [1]. Linear deposition of
immunoglobulin G (IgG) along GBM is the hallmark of
anti-GBM glomerulonephritis, and is occasionally accom-
panied by deposition along tubular basement membrane
(TBM). The pathogenicity of anti-GBM IgG has been
demonstrated in passive transfer studies using the renal
elute taken from patients, which is subsequently injected
into squirrel monkeys. The authors observed a similar* Correspondence: cuizhao_pku@163.com
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reproduction in any medium, provided the orlinear deposition of IgG along the GBM, which contributed
to the development of crescentic glomerulonephritis [2].
The target antigen has been identified as the non-
collagenous domain (NC1) of α3 chain of type IV collagen
on GBM [α3(IV)NC1]. There are two major conform-
ational epitopes within the antigen, EA and EB, which are
sequestrated in the quaternary structure of GBM by critical
sulfilimine bond [3,4].
Human IgG are categorized into four subclasses (IgG1,
IgG2, IgG3 and IgG4) according to their heavy chains,
which elicit different immunological and inflammatory
responses. Previous studies have reported that there is
anti-GBM IgG subclass restriction in the circulation of
patients with anti-GBM disease, in which IgG1 and IgG4
were predominant [5]. Our recent studies showed that
during the initiation and progression of anti-GBM glom-
erulonephritis, there is an attendant increase of frequen-
cies of anti-GBM IgG1 and IgG3 [6]. This correlation
highlights the pathogenic role of IgG1 and IgG3 in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Qu et al. BMC Immunology 2013, 14:19 Page 2 of 8
http://www.biomedcentral.com/1471-2172/14/19development of renal injury. Animal models also showed
that the severity of anti-GBM antibodies induced glom-
erulonephritis was dependent on the different types of
IgG subclasses [7]. However, in human anti-GBM dis-
ease, IgG subclass distribution along GBM has not been
clearly elucidated, and their association with disease se-
verity remains elusive.
The aim of the current study is to investigate the dis-
tribution of IgG subclass deposition along GBM and
TBM on renal biopsy specimens from patients with anti-
GBM disease in different clinical spectrum. Their associ-
ation with the clinical and pathological parameters and
the outcomes of patients was further explored.
Results
Demographic and clinical data of patients
The demographic, clinical and pathological parameters
of the 46 patients with anti-GBM disease are listed in
Table 1.
Of the 46 patients, the average age was 35.3±15.7 years,
with a male to female ratio of 2.3:1 (32 male and
14 female). Fifteen (32.6%) patients had pulmonary
hemorrhage and presented as Goodpasture’s syndrome.
The mean level of serum creatinine at presentation was
728.5±378.8 μmol/L. The median level of serum anti-
GBM antibodies was 63U/mL (range from 15 to
176U/mL, normal <13U/mL). Nine (19.6%) patientsTable 1 Demographic, clinical parameters and outcomes




Hydrocarbon exposure, n (%) 3/44 (6.8%)
Prodromal infection, n (%) 19/46 (41.3%)
Smoking, n (%) 24/45 (53.3%)
Hemoptysis, n (%) 15/46 (32.6%)
Oliguria/anuria, n (%) 14/46 (30.4%)
Gross hematuria, n (%) 15/31 (32.6%)
Nephrotic syndrome, n (%) 19/31 (61.3%)
Serum creatinine at presentation (μmol/L) 728.5±378.8
Level of anti-GBM antibodies (U/mL) median (range) 63 (15, 176)
Positive with ANCA, n (%) 9/46 (19.6%)
Hemoglobin (g/L) 85.6±26.1
Percentage of crescents in glomeruli (%) 78.8±29.6
Cellular crescents (%) 60.3±33.8
Fibrotic crescents (%) 33.2±31.0
Renal survival (1 year), n (%) 10/46 (21.7%)
Patient survival (1 year), n (%) 36/46 (78.3%)
GBM: glomerular basement membrane; ANCA: anti-neutrophil cytoplasmic
antibody.were ANCA positive, with 8 specific to MPO and 1
specific to PR3.
On renal biopsy, an average of 22±9.8 glomeruli could be
seen in each specimen. 78.8±29.6% of the glomeruli formed
crescent and 41 (89.1%) patients were diagnosed of cres-
centic glomerulonephritis. The percentage of crescents in
glomeruli was positively correlated with the level of serum
creatinine on diagnosis (r=0.637, P<0.001). Linear IgG
immunofluorescence along GBM was demonstrated for
each of the 46 patients with staining intensity of 1+~4+ on
the scale of 1 to 4, in the absence of fluorescence for albu-
min or a diagnosis of diabetes. Complement (C) 3 was
detected in 26 patients (26/46, 56.5%). The staining inten-
sity of IgG along GBM was correlated with that of C3
(r=0.456, P=0.002). The staining intensity of neither IgG
nor C3 presented correlation with the percentage of cellular
cresents (for IgG: P=0.322; for C3: P=0.635) or fibrotic
crescents (for IgG: P=0.596; for C3: P=0.272).The distribution of IgG subclass deposition along GBM
All the four IgG subclasses deposition along GBM were
detected on renal biopsy sections from the 46 patients
(Table 2) (Figure 1).
Anti-GBM IgG3 was observed along GBM on renal sec-
tions in all the 46 patients (100%). Thirty-nine (84.8%)
patients showed weak and segmental staining on glomeruli,
and 7 (15.2%) patients showed strong and linear deposition.
Anti-GBM IgG2 was found on glomeruli in 22 (47.8%)
patients, with 20 (90.9%) patients having weak and
segmental deposition and 2 (9.1%) patients presenting
strong and linear staining.
Anti-GBM IgG1 and IgG4 were less abundant on the
glomeruli. For IgG1, only 9 (19.6%) renal samples stained
positive and the intensity was weak, spotty and segmental
staining along GBM. For IgG4, only 7 (15.2%) patientsTable 2 Distribution and intensity of each IgG subclass
deposition along GBM and TBM from patients with anti-
GBM disease
Negative Weak/Segmental Strong/Linear All positive
Glomerular basement membrane
IgG1 37 (80.4%) 9 (19.6%) 0 9 (19.6%)
IgG2 24 (52.2%) 20 (43.5%) 2 (4.3%) 22 (47.8%)
IgG3 0 39 (84.8%) 7 (15.2%) 46 (100%)
IgG4 39 (84.8%) 6 (13%) 1 (2.2%) 7 (15.2%)
Tubular basement membrane
IgG1 44 (95.7%) 1 (2.2%) 1 (2.2%) 2 (4.4%)
IgG2 32 (69.6%) 10 (21.7%) 4 (8.7%) 14 (30.4%)
IgG3 15 (32.6%) 23 (50%) 8 (17.4%) 31 (67.4%)
IgG4 43 (93.5%) 2 (4.3%) 1 (2.2%) 3 (6.5%)
Figure 1 Immunohistochemistry for IgG subclasses on renal biopsy sections from patients with anti-GBM disease (×400). A. The weakly
segmental deposition of IgG1 along GBM; B. The strong linear deposition of IgG2 along GBM; C. The strong linear deposition of IgG3 along GBM;
D. The weakly linear deposition of IgG4 along GBM; E. Negative control. F. IgG3 partially deposits along TBM and inflammatory cell infiltration in
the interstitium near TBM.
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strong linear deposition along the GBM.
No correlation was found among the four IgG subclasses
of their distribution and intensity along GBM (P>0.05).
The correlation between IgG subclass deposition along
GBM and clinical parameters
Correlation between the deposition of each IgG subclass
along GBM and the clinical, pathological data and
outcomes of patients were analyzed, including age, gender,
exposure to hydrocarbon, smoking, serum level of anti-
GBM antibodies, positive ANCA, prevalence of nephrotic
syndrome, hematuria and oliguria/anuria, serum creatin-
ine at presentation, renal histopathology, and the renal/
patient outcomes (Table 3).We found that the patients with strong linear staining
of IgG3 along GBM presented with lower prevalence of
gross hematuria (0% vs. 38.5%, P=0.046), higher level of
hemoglobin (105.1±25.8 vs. 82.0±24.9 g/L, P=0.038),
and lower level of serum creatinine (445.4±333.0 vs.
779.4±367.4 μmol/L, P=0.028), compared with those
with weak staining of IgG3. Although not statistically
significance, the levels of anti-GBM antibodies also
seemed to be lower in patients with strong IgG3 depos-
ition than those with weak deposit (39.8±42.9 vs
70.0±38.7U/mL, P=0.060).
No correlation was found between the GBM depos-
ition of IgG1, IgG2 or IgG4 subclass and the clinical,
pathological parameters or outcomes of patients with
anti-GBM disease (P>0.05).
Table 3 Correlation between the deposition of IgG subclasses along GBM and the clinical and pathological parameters of patients


















Age (years) 38.8±13.8 34.5±16.2 0.286 38.1±15.6 32.7±15.7 0.202 37.6±10.4 34.9±16.6 0.320 31.4±16.1 36±15.7 0.529
Gender (male/female) 5/4 27/10 0.308 15/7 17/7 0.845 5/2 27/12 0.907 6/1 26/13 0.313
Hydrocarbon exposure, n (%) 1/9 (11.1%) 2/35 (5.7%) 0.567 1/21 (4.8%) 2/23 (8.7%) 0.605 1/7 (14.3%) 2/37 (5.4%) 0.393 0/7 (0%) 3/37 (8.1%) 0.435
Prodromal infection, n (%) 6/9(66.7%) 13/37 (35.1%) 0.085 8/22 (36.4%) 11/24 (45.8%) 0.515 3/7 (42.9%) 16/39 (41.0%) 0.928 2/7 (28.6%) 17/39 (43.6%) 0.457
Smoking, n (%) 4/8 (50%) 20/37 (54.1%) 0.835 12/21 (57.1%) 12/24 (50%) 0.632 4/7 (57.1%) 20/38 (52.6%) 0.826 4/7 (57.1%) 20/8 (52.6%) 0.826
Gross hematuria, n (%) 2/9 (22.2%) 13/37 (35.1%) 0.459 9/22 (40.9%) 6/24 25%) 0.250 0/7 (0%) 15/39 (38.5%) 0.046 3/7 (42.9%) 12/39 (30.8%) 0.530
Nephrotic syndrome, n (%) 3/5(60.0%) 16/26 (61.5%) 0.948 8/14 (57.1%) 11/17 (64.7%) 0.667 4/6 (66.7%) 15/25 (60%) 0.763 4/5 (80%) 15/26(57.7%) 0.348
Hemoglobin (g/L) 94±28.5 83.5±25.2 0.493 90.6±24.2 80.9±27.6 0.146 105.1±25.8 82.0±24.9 0.038 84.3±29.7 85.9±25.9 0.818
Oliguria/anuria, n (%) 3/9(33.3%) 11/37 (29.7%) 0.833 7/22 (31.8%) 7/24 (29.2%) 0.845 0/7 (0%) 14/39 (35.9%) 0.057 2/7 (28.6%) 12/39 (30.8%) 0.907
Serum creatinine at presentation
(μmol/L)
503.8±341.9 783.2±371.0 0.031 674.9±373.7 777.8±384.6 0.350 445.4±333.0 779.4±367.4 0.028 825±532.6 711.2±350.8 0.490
Anti-GBM antibodies (U/mL) 56.1±34.9 69.7±40.8 0.359 90.6±24.2 80.9±27.6 0.452 39.8±42.9 70±38.7 0.060 64.5±59.5 67.4±36.3 0.566
ANCA, n (%) 2/9 (22.2%) 7/37 (18.9%) 0.823 4/18 (22.2%) 5/24 (20.8%) 0.821 0/9 (0%) 9/39 (23.1%) 0.156 2/7 (28.6%) 7/39 (17.9%) 0.514
Percentage of total crescents (%) 60.6±44.3 832±23.6 0.397 76.4±30.1 81.0±29.7 0.587 54.7±47.0 83.1±23.8 0.183 68.9±38.7 80.5±28 0.719
Cellular crescents (%) 43.3±36.1 64.5±32.3 0.086 65.3±34.0 55.8±33.6 0.285 39.6±34.8 64.0±32.6 0.093 58.9±38.6 60.6±33.4 1
Fibrotic crescents (%) 34.5±32.9 32.8±30.9 0.892 25.6±27.9 40.1±32.5 0.113 31.8±30.8 33.4±31.4 0.858 41.1±38.6 31.7±29.8 0.590
C3 deposits (median) 2 1 1.000 0 1 0.627 2 1 0.131 2 1 0.131
Ultrastructrual lesions 2 2 0.438 2 2 0.727 2 2 0.438 2 2 0.438
Renal survival (1 year), n (%) 3/9 (33.3%) 7/37 (18.9%) 0.347 5/22 (22.7%) 5/24 (20.8%) 0.876 4/7 (57.1%) 7/39 (17.9%) 0.141 1/7 (14.3%) 9/39 (23.1%) 0.604
Patient survival (1 year), n (%) 6/9 (66.7%) 30/37 (81.1%) 0.347 17/22 (77.3%) 19/24 (79.2%) 0.876 7/7 (100%) 29/39 (74.4%) 0.130 4/7 (57.1%) 32/39 (82.1%) 0.141
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Anti-GBM IgG deposition along TBM could be detected
in 31 (67.4%) patients (Table 2, Figure 1). Among these
patients, the IgG subclass distribution along TBM was
similar to that of the GBM: IgG1 6.5% (2/31), IgG2
45.2% (14/31), IgG3 100% (31/31) and IgG4 9.7% (3/31).
No correlation was found between the IgG subclass distri-
bution along TBM and the clinical data or the outcomes
of patients (P>0.05). The degree of interstitial inflamma-
tion was more severe in patients with stronger deposits of
IgG3 along TBM (P=0.031, Table 4).
The correlation between IgG subclass deposition on GBM
and their level in the sera
Out of 46 patients whose renal specimens were examined,
serum from 32 individuals were collected and tested for
IgG subclass distribution in circulation. The positive rate
of IgG1, IgG2, IgG3 and IgG4 were 87.5% (28/32), 81.25%
(26/32), 75% (24/32) and 81.25% (26/32), with the average
level of 0.77±0.90, 0.23±0.36, 0.17±0.23 and 0.61±0.94, re-
spectively. We analyzed the correlation between the serum
antibody levels and the intensity of IgG subclass depos-
ition on GBM and TBM. No relations was found between
them (P>0.05).
Discussion
In the current study, we examined the distribution of
IgG subclass deposition along GBM and TBM on renal
biopsy specimens from a large cohort of 46 patients with
anti-GBM disease. We found that all four IgG subclasses
could be detected with vastly different distributions. For
the deposition on the GBM, IgG3 was detected in all pa-
tients with mild segmental to strong linear staining.
IgG2 was found in approximately half of the patients.
IgG1 was only detected in one fourth of the patients and
the intensity of deposition was weak and segmental.
IgG4 was the least abundant subclass detected on the
GBM.
The general detection of IgG3 along the GBM and the
TBM suggests that it is likely to play an important role in
the pathogenesis of renal lesions, which contribute to the
development of human anti-GBM disease. The structural
characteristics that distinguish the four subclasses are theTable 4 The severity of inflammatory cell infiltration in












Patients without TBM-IgG3 4 3 2 6
Patients with mild
deposited TBM-IgG3
3 7 9 4
Patients with strong
deposited TBM-IgG3
0 0 6 2size of the hinge region and the number and position of
the interchain disulfide bonds between heavy chains. With
an elongated 62-amino-acid hinge region, IgG3 molecules
are the most effective complement activator [8]. There-
fore, Clq could bind more readily to the Fc region of IgG3
and thus facilitate the complement-associated inflamma-
tory response. The general finding of linear or granular C3
deposition accompanying IgG on GBM supports the acti-
vation of complement system in glomeruli during the pro-
gress of anti-GBM nephritis [9,10]. Another mechanism
for IgG3 inducing tissue damage lies in its high affinity
binding to Fc receptors (R) on phagocytic cells to mediate
opsonization [11]. The IgG Fc-FcR interaction in
glomeruli could also mediate the accumulation of macro-
phages to induce renal injury [12]. Accelerated models of
anti-GBM glomerulonephritis induced in FcγRI−/−,
FcγRIII−/− and FcRγ−/− mice have demonstrated that
FcRγ, especially FcγRIII, plays a pivotal role in the patho-
genesis through the antibody-dependent pathway [13].
Moreover, the copy number variation of FCGR3A [14]
and the gene polymorphism of FCGR2B [15] have been
demonstrated as contributors to the susceptibility of anti-
GBM disease in Chinese population. These mechanisms
may be involved in the pathogenesis of renal injury after
IgG3 deposition along GBM and TBM.
In our study, we also detected the circulating IgG
subclasses against rHα3(IV)NC1, which showed that all
the four subclasses were presented. In comparison with
our previous study [6], we found that most patients from
our present study had severe renal damage, with all the
four IgG subclasses in circulation. The level of circulat-
ing IgG subclasses was not correlated with the depos-
ition of IgG subclasses on renal tissue. The predominant
of IgG3 deposition on glomeruli is in contrast with
previous reports about the anti-GBM IgG subclass
distribution in circulation [5,16]. It is demonstrated that
anti-GBM IgG in sera is mainly of IgG1 (94%) and IgG4
(88%) subclasses. IgG3 was found in only 12% of the sera
from patients [16]. We assume it might be difficult to
detect IgG3 in the serum because of its short life time
(8 days), but it located on glomeruli and induced damage
with formation of crescents. Although it had no statis-
tical significance, the circulating IgG1 and tissue IgG1
showed a mild correlation, which P=0.107, which might
be contributed to the longer life time of IgG1 in circula-
tion (23 days) for easier detection [8]. Despite its
deficiency in sera, the close relationship between IgG3
and the progression of human anti-GBM nephritis was
proven, as IgG3 being absent in natural anti-GBM
antibodies from healthy individuals [7,17], while
occurring in patients with renal dysfunction [6]. Animal
experiments also showed that monoclonal IgG2a and
IgG2b (equivalent to human IgG1 and IgG3 [18]) against
α3(IV)NC1 could induce severe nephritis and pulmonary
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immune disease, the immune response of anti-GBM
autoantibodies is directed to the target antigen in situ of
the glomerular and alveolar basement membrane. Thus,
the target organs may be damaged much directly by
humoral or cellular mechanisms in the local immunity
rather than the systemic immunity.
The correlation between the IgG subclass deposition and
the clinical and pathological parameters of patients was an-
alyzed in the current study. It was shown that patients with
strong linear deposition of IgG3 on GBM presented with
milder disease severity with lower serum creatinine and
lower circulating anti-GBM antibodies on diagnosis. This
finding emphasizes the important role of IgG3 in the early
stage of kidney impairment in human anti-GBM disease.
Cellular immunity has also been demonstrated to partici-
pate in the formation of severe crescentic glomeruloneph-
ritis [20]. It may be speculated that the structure of
glomerular capillary walls are severely damaged and frac-
tured in the later stage of crescent formation, which may
result in the deposition of IgG showing weaker segmental
staining in more severe renal lesions. This may also be the
explanation for the different findings from Noël et al., who
found that IgG subclass deposited in glomeruli were mostly
IgG1 and IgG4 [21]. The discrepancies might be explained
by the different demographics and ethnicity of patients, dif-
ferent detecting monoclonal antibodies and differences in
investigating approaches. In our study, we performed im-
munohistochemistry instead of immunofluorescence, which
was employed by the previous study (Noël et al. [21]). We
both utilized direct immunofluorescence with strict positive
and negative controls. However, the large number of pa-
tients in the current study contains patients with different
stages of renal impairment, i.e. from the mildest, to severe
kidney dysfunction requiring dialysis, provided better op-
portunities to reveal the distribution of IgG subclasses in a
wide spectrum of kidney lesions.
IgG deposition on TBM was also detected in 67.4% of
the patients, with accordant distribution as it was along
GBM. TBM deposition is not common in anti-GBM
nephritis [22]. We suggested that the high detection rate
of IgG deposits along TBM may be due to the high sen-
sitivity of immunohistochemistry used in the current
study. Using this method, we further found that the in-
flammatory cell infiltration in interstitium was more se-
vere in patients with strong anti-TBM IgG3 deposits,
which implies that the deposition of autoantibodies on
TBM may contribute to the inflammatory cell infiltra-
tion in renal interstitial and/or causes direct tubular
damage.
Conclusions
Anti-GBM IgG3 predominantly deposits along GBM
and TBM on renal biopsy specimens from patients withanti-GBM disease, which may play a pivotal role in the
development of anti-GBM glomerulonephritis.
Methods
Patients
Forty-six patients with renal biopsy-proven anti-GBM
disease diagnosed in Peking University First Hospital
from 1994 to 2008 were enrolled in this study. They
were diagnosed in our hospital or referred to our hos-
pital by physicians or nephrologists from other hospitals
throughout China. The clinical manifestations and
pathologic data were collected from medical records at
the time of presentation and during follow-up. The re-
search was in compliance with the Declaration of
Helsinki and approved by the ethics committee of our
hospital (reference number 418).
Detection of anti-GBM antibodies and ANCA
Sera from all patients were screened at presentation
before the initiation of immunosuppressive treatment.
Anti-GBM assays were performed by enzyme-linked
immunosorbent assay (ELISA) using purified bovine
α(IV)NC1 as solid phase antigen, with confirmation of anti-
body specificity by ELISA against recombinant human
α3(IV)NC1. Anti-neutrophil cytoplasmic antibody (ANCA)
assays were performed by indirect immunofluorescence
(EUROIMMUN, Lübeck, Germany) using ethanol-fixed
human neutrophils. Antigen-specific ELISA was performed
against purified myeloperoxidase (MPO) and proteinase
3 (PR3).
Renal histopathology
Renal biopsy was performed at the time of diagnosis. Renal
specimens were evaluated using direct immunofluores-
cence, light and electron microscopy and were forwarded
to two pathologists. The biopsies were independently
assessed in a blinded manner by two pathologists.
For direct immunofluorescence, frozen sections were
examined by a fluorescent microscope (Nikon, Tokyo,
Japan) after staining with fluorescein isothiocyanate
(FITC)-conjugated antibodies specific for human IgG,
IgM, IgA, C3, C1q, fibrinogen and albumin (Dako,
Copenhagen, Denmark). The fluorescence was semi-
quantitatively graded from 0 to 4+ according to the inten-
sity. For light microscopy, consecutive series of 4 μm
paraffin sections were stained with haematoxylin and
eosin, periodic acid-Schiff with silver methenamine and
Masson’s trichrome. For electron microscopy, biopsy
specimens were fixed in 2.5% glutaraldehyde, post-fixed in
1% osmium tetroxide. Then it was dehydrated in graded
acetone, and embedded in Epon 812 resin. Ultrathin
sections were stained with uranyl acetate and lead
citrate, examined by a transmission electron microscope
(JEM-1230, JEOL, Tokyo, Japan).
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of crescents in glomeruli. The tubular-interstitial injury
was scored 1~4 based on the involved area, as score 1
(<25%), score 2 (25~50%), score 3 (50~75%) and score 4
(>75%). The ultrastructural lesion were scored based on
the crescent formation and inflammatory cell infiltration
in glomeruli, as score 1 for mild injury and score 2 for
severe injury.
Immunohistochemistry for anti-GBM IgG subclasses on
renal biopsy sections
Paraffin-embedded specimens of formalin-fixed renal bi-
opsy tissue were processed for immunohistochemical
staining for IgG subclasses using mouse monoclonal anti-
bodies against human IgG1, IgG2, IgG3 and IgG4
(γ chains specific, Southern Biotech, Birmingham, USA).
The clone numbers were 4E3, HP6014, HP6050 and
HP6025, respectively. The optimal time and temperature
for incubation were predetermined. Renal sections were
treated at room temperature firstly with 0.4% pepsin
(Zhongshan Golden Bride Biotechnology, Beijing, China),
30 min, for antigen retrieval, then with freshly prepared
3% hydrogen peroxide in methanol solution, 20 min, to
quench endogenous peroxidase activity, and last 1%
bovine serum albumin (BSA) at 37°C for 30 min to block
non-specific staining. Monoclonal antibodies were diluted
1:100 in 0.01 mol/L phosphate buffered saline (PBS),
pH 7.4, for incubation at 4°C over night. The secondary
antibodies of goat anti-mouse immunoglobulins conju-
gated with horseradish peroxidase (Dako, Copenhagen,
Denmark) were diluted 1:100 and incubated at 37°C for
1 h. Then, the sections were developed in fresh hydrogen
peroxide plus 3-3-diaminobenzidine tetrahydrochloride
solution for 30 sec. Renal sections from patients with
membranous nephropathy and membranous lupus neph-
ritis were used as positive controls, normal renal sections
and those from patients with minimal change disease and
thin basement membrane disease were used as negative
controls, PBS was used as blank in replacement for mono-
clonal antibodies. The extensity and intensity of staining
was evaluated at ×400 magnification and scored
semiquantitatively: 0, no staining; 1, weakly, spotty and
segmental staining; 2, moderate or strong linear staining.
Detection of anti-GBM IgG subclasses in sera by ELISA
Detection of anti-GBM IgG subclasses by ELISA is
performed as previously described [6]. The rHα3(IV)
NC1 was coated at 2 μg/ml, the test sera were diluted at
1:50 with PBS containing 0.1% Tween 20, and the horse-
radish peroxidase-conjugated monoclonal mouse anti-
human IgG1, IgG2, IgG3 and IgG4 (Clone No.4E3,
HP6014, HP6050 and HP6025) antibodies were diluted
at 1:500. The results were recorded as the net OD
405 nm (Bio-Rad, Tokyo, Japan) (the average value ofantigen coated wells minus the average value of antigen-
free wells).
Statistical analysis
Differences of quantitative parameters were assessed
using the Student t test (for data that were normally dis-
tributed) or nonparametric test (for data that were not
normally distributed). Differences of semi-quantitative
data were tested using Mann–Whitney U test. Differ-
ences of qualitative data were compared using chi-
square test or Fisher’s exact tests. Spearman’s correlation
test was used to measure the correlation between two
non-parametric variables or one non-parametric variable
with one parametric variable. Statistical significance was
considered as P<0.05. Analysis was performed using
SPSS statistical software package (version 13.0, SPSS,
Chicago, IL, USA).
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